These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30202088)

  • 1. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.
    Kouyos RD; Rusert P; Kadelka C; Huber M; Marzel A; Ebner H; Schanz M; Liechti T; Friedrich N; Braun DL; Scherrer AU; Weber J; Uhr T; Baumann NS; Leemann C; Kuster H; Chave JP; Cavassini M; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Rauch A; Yerly S; Aubert V; Klimkait T; Böni J; Metzner KJ; Günthard HF; Trkola A;
    Nature; 2018 Sep; 561(7723):406-410. PubMed ID: 30202088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlates of broadly neutralizing antibody development.
    Abela IA; Kadelka C; Trkola A
    Curr Opin HIV AIDS; 2019 Jul; 14(4):279-285. PubMed ID: 31107283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.
    Reh L; Magnus C; Schanz M; Weber J; Uhr T; Rusert P; Trkola A
    PLoS Pathog; 2015 Jul; 11(7):e1004966. PubMed ID: 26158270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
    McGuire AT
    Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
    Moore PL; Williamson C; Morris L
    Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.
    Cornelissen M; Euler Z; van den Kerkhof TL; van Gils MJ; Boeser-Nunnink BD; Kootstra NA; Zorgdrager F; Schuitemaker H; Prins JM; Sanders RW; van der Kuyl AC
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1135-1142. PubMed ID: 26910384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
    Reh L; Magnus C; Kadelka C; Kühnert D; Uhr T; Weber J; Morris L; Moore PL; Trkola A
    PLoS Pathog; 2018 Jan; 14(1):e1006825. PubMed ID: 29370298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
    Tu JJ; Kumar A; Giorgi EE; Eudailey J; LaBranche CC; Martinez DR; Fouda GG; Moreau Y; Thomas A; Montefiori D; Gao F; Sagar M; Permar SR
    J Virol; 2022 Jun; 96(11):e0023122. PubMed ID: 35536018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of HIV-1 broadly neutralizing antibody induction.
    Rusert P; Kouyos RD; Kadelka C; Ebner H; Schanz M; Huber M; Braun DL; Hozé N; Scherrer A; Magnus C; Weber J; Uhr T; Cippa V; Thorball CW; Kuster H; Cavassini M; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Rauch A; Yerly S; Aubert V; Klimkait T; Böni J; Fellay J; Regoes RR; Günthard HF; Trkola A;
    Nat Med; 2016 Nov; 22(11):1260-1267. PubMed ID: 27668936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.
    Landais E; Huang X; Havenar-Daughton C; Murrell B; Price MA; Wickramasinghe L; Ramos A; Bian CB; Simek M; Allen S; Karita E; Kilembe W; Lakhi S; Inambao M; Kamali A; Sanders EJ; Anzala O; Edward V; Bekker LG; Tang J; Gilmour J; Kosakovsky-Pond SL; Phung P; Wrin T; Crotty S; Godzik A; Poignard P
    PLoS Pathog; 2016 Jan; 12(1):e1005369. PubMed ID: 26766578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.
    Kadelka C; Liechti T; Ebner H; Schanz M; Rusert P; Friedrich N; Stiegeler E; Braun DL; Huber M; Scherrer AU; Weber J; Uhr T; Kuster H; Misselwitz B; Cavassini M; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Rauch A; Yerly S; Aubert V; Klimkait T; Böni J; Kouyos RD; Günthard HF; Trkola A;
    J Exp Med; 2018 Jun; 215(6):1589-1608. PubMed ID: 29794117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
    Landais E; Moore PL
    Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.